Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists use brain scans to uncover how we hear our own voice

NCT ID NCT06458153

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses fMRI and EEG to understand how brain areas that plan movement interact with those that process sound during speech. Researchers will compare healthy adults and people who have had a cerebellar stroke. The goal is to learn how the brain adjusts hearing during speaking and detects speech errors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could improve our understanding of how the brain coordinates speech, potentially guiding future therapies for speech problems after stroke.
What could go wrong
This is an observational brain imaging study, not a treatment trial. It is early-stage and may not directly lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cohort 1 (neurotypical adults): * Age 18-49 * Right-handed * Native English speaker Cohort 2 (people with cerebellar lesions): * Age 18 or older * Right-handed * Native English speaker * History of cerebellar stroke Cohort 3 (controls matched to Cohort 2) * Age 18 or older * Right-handed * Native English speaker Exclusion Criteria: Cohort 1 (neurotypical adults): * Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant * History of neurological / neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury) * Hearing loss, defined by pure tone thresholds \>25 decibels (dB) hearing level (HL) at octave frequencies between 250-8000 Hz * Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders * Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium) * Presence of a severe and unmanaged, clinically diagnosed attention disorder * Clinically diagnosed with or treated for a speech, language, or hearing disorder * Head circumference greater than 60cm or weight greater than 300 pounds * History of severe claustrophobia * Currently pregnant Cohort 2 (people with cerebellar lesions): * Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant * History of neurological / neurodegenerative disease or severe brain injury other than stroke * Hearing loss, defined by pure tone thresholds \>50 dB HL at octave frequencies between 250-4000 Hz * Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders * Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium) * Presence of a severe and unmanaged, clinically diagnosed attention disorder * Head circumference greater than 60cm or weight greater than 300 pounds * History of severe claustrophobia * Currently pregnant Cohort 3 (controls matched to Cohort 2): * Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant * History of neurological / neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury) * Hearing loss, defined by pure tone thresholds \>50 dB HL at octave frequencies between 250-4000 Hz * Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders * Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium) * Presence of a severe and unmanaged, clinically diagnosed attention disorder * Clinically diagnosed with or treated for a speech, language, or hearing disorder * Head circumference greater than 60cm or weight greater than 300 pounds * History of severe claustrophobia * Currently pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebellum are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.